Gleave M - Search Results

1

Modeling Androgen Deprivation Therapy-Induced Prostate Cancer Dormancy and Its Clinical Implications.

Dong X, Xue H, Mo F, Lin YY, Lin D, Wong NKY, Sun Y, Wilkinson S, Ku AT, Hao J, Ci X, Wu R, Haegert A, Silver R, Taplin ME, Balk SP, Alumkal JJ, Sowalsky AG, Gleave M, Collins C, Wang Y. Dong X, et al. Among authors: gleave m. Mol Cancer Res. 2022 May 4;20(5):782-793. doi: 10.1158/1541-7786.MCR-21-1037. Mol Cancer Res. 2022. PMID: 35082166 Free PMC article.

2

Biochemical and pathological effects of 8 months of neoadjuvant androgen withdrawal therapy before radical prostatectomy in patients with clinically confined prostate cancer.

Gleave ME, Goldenberg SL, Jones EC, Bruchovsky N, Sullivan LD. Gleave ME, et al. J Urol. 1996 Jan;155(1):213-9. J Urol. 1996. PMID: 7490838 Clinical Trial.

3

Intermittent androgen suppression in the treatment of prostate cancer: a preliminary report.

Goldenberg SL, Bruchovsky N, Gleave ME, Sullivan LD, Akakura K. Goldenberg SL, et al. Among authors: gleave me. Urology. 1995 May;45(5):839-44; discussion 844-5. doi: 10.1016/s0090-4295(99)80092-2. Urology. 1995. PMID: 7538246 Clinical Trial.

4

Optimal duration of neoadjuvant androgen withdrawal therapy before radical prostatectomy in clinically confined prostate cancer.

Gleave ME, Goldenberg SL, Jones EC, Bruchovsky N, Kinahan J, Sullivan LD. Gleave ME, et al. Semin Urol Oncol. 1996 May;14(2 Suppl 2):39-45; discussion 46-7. Semin Urol Oncol. 1996. PMID: 8725890 Review.

5

Intermittent androgen suppression delays progression to androgen-independent regulation of prostate-specific antigen gene in the LNCaP prostate tumour model.

Sato N, Gleave ME, Bruchovsky N, Rennie PS, Goldenberg SL, Lange PH, Sullivan LD. Sato N, et al. Among authors: gleave me. J Steroid Biochem Mol Biol. 1996 May;58(2):139-46. doi: 10.1016/0960-0760(96)00018-0. J Steroid Biochem Mol Biol. 1996. PMID: 8809195

6

A metastatic and androgen-sensitive human prostate cancer model using intraprostatic inoculation of LNCaP cells in SCID mice.

Sato N, Gleave ME, Bruchovsky N, Rennie PS, Beraldi E, Sullivan LD. Sato N, et al. Among authors: gleave me. Cancer Res. 1997 Apr 15;57(8):1584-9. Cancer Res. 1997. PMID: 9108464

7

Neoadjuvant androgen withdrawal therapy decreases local recurrence rates following tumor excision in the Shionogi tumor model.

Gleave ME, Sato N, Goldenberg SL, Stothers L, Bruchovsky N, Sullivan LD. Gleave ME, et al. J Urol. 1997 May;157(5):1727-30. J Urol. 1997. PMID: 9112514

8

Intermittent androgen suppression for prostate cancer: rationale and clinical experience.

Gleave M, Bruchovsky N, Goldenberg SL, Rennie P. Gleave M, et al. Eur Urol. 1998;34 Suppl 3:37-41. doi: 10.1159/000052297. Eur Urol. 1998. PMID: 9854195 Review.

9

Antisense Bcl-2 oligodeoxynucleotides inhibit progression to androgen-independence after castration in the Shionogi tumor model.

Miyake H, Tolcher A, Gleave ME. Miyake H, et al. Among authors: gleave me. Cancer Res. 1999 Aug 15;59(16):4030-4. Cancer Res. 1999. PMID: 10463603

10

Progression to androgen independence is delayed by adjuvant treatment with antisense Bcl-2 oligodeoxynucleotides after castration in the LNCaP prostate tumor model.

Gleave M, Tolcher A, Miyake H, Nelson C, Brown B, Beraldi E, Goldie J. Gleave M, et al. Clin Cancer Res. 1999 Oct;5(10):2891-8. Clin Cancer Res. 1999. PMID: 10537358

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

682 results

Search Page